[Management of chronic hepatitis B]

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis B virus (HBV) infection presents significant challenges in liver disease management.
• Understanding the therapeutic landscape for HBV-related liver diseases is crucial for patient outcomes.

Observation:

• Interferon (IFN) therapy in Hungary (1994-1996) led to clinical-biochemical remission in 50% of 68 chronic hepatitis B patients.
• HBV replication was eliminated in 32% of patients treated with IFN.
• Nucleoside analogues like famciclovir and lamivudine are under investigation for HBV treatment.

Findings:

• Combination therapy with nucleoside analogues and IFN may enhance treatment efficacy.
• Immunomodulatory agents and other therapies have shown limited established benefit.
• Recombinant HBsAg vaccine is being explored for therapeutic applications.

Implications:

• Liver transplantation remains the sole option for end-stage HBV liver cirrhosis, yet reinfection remains a concern.
• Further research into combination therapies and novel vaccines is essential for advancing HBV treatment.
• Addressing the challenge of post-transplant HBV recurrence is critical for long-term graft survival.